tti-622
Recombinant proteinexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2018 (NCT03530683)
Timeline
Indications
Studied for
- Carcinoma, Ovarian Epithelial · Phase 2
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Leukemia, Myeloid, Acute · Phase 1
- Lymphoma · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell · Phase 2
- Multiple Myeloma · Phase 1
- Ovarian Neoplasms · Phase 2
Mechanism of action
- Leukocyte surface antigen CD47INHIBITOR
CD47 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05507541 | Phase 2 | Jan 15, 2023 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT05567887 | Phase 1 | Nov 2, 2022 | Pfizer |
| NCT05261490 | Phase 2 | Aug 1, 2022 | Pfizer |
| NCT05139225 | Phase 1 | Oct 28, 2021 | Memorial Sloan-Kettering Cancer Center, Trillium Therapeutics Inc. |
| NCT03530683 | Phase 1 | May 1, 2018 | Trillium Therapeutics Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 2 | 2 | 2 | 2022 |
| Trillium Therapeutics Inc. | For profit | 2 | 1 | 1 | 2018 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2023 |
5 organizations
Page 1 / 1